The U.S. House Oversight Committee to subpoena drugmaker, AbbVie, after it refused to cooperate with the Congressional investigation into their #drugpricing practices surrounding Humira and Imbruvica. 1/3
AbbVie filed a 165 patent applications to protect Imbruvica from generic competition. Additional patent protections led to nine additional years of monopoly and $41 billion in spending on this drug. i-mak.org/imbruvica/ 2/3
For its blockbuster Humira, AbbVie filed 247 patent applications blocking generic competition for nearly 40 years. Since its launch, Humira's price has increased substantially with no justification: i-mak.org/humira/ 3/3
• • •
Missing some Tweet in this thread? You can try to
force a refresh
